A RIVA-DM Subanalysis Investigating Patients With Nonvalvular Atrial Fibrillation and Type 2 Diabetes Aged Under Versus Over 80 Years.

Craig I ColemanOlivia S CostaChristopher W BresciaBurcu VardarKhaled AbdelgawwadLucas HofmeisterNitesh Sood

Published in: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2022)

The effectiveness and safety of rivaroxaban versus warfarin remained consistent across patient age subgroups.

Keyphrases

atrial fibrillation
oral anticoagulants
direct oral anticoagulants
type diabetes
catheter ablation
left atrial
left atrial appendage
venous thromboembolism
heart failure
glycemic control
percutaneous coronary intervention
cardiovascular disease
metabolic syndrome
pulmonary embolism
weight loss